Purple Biotech (PPBT) Income from Discontinued Operations (2020 - 2021)
Purple Biotech's (PPBT) quarterly Income from Discontinued Operations came in at $508000.0 in Q4 2021, up 1236.84% year-over-year from $38000.0 in Q4 2020, and up 229.87% quarter-over-quarter from $154000.0 in Q3 2021.
Powered by 
Analysis
Purple Biotech (PPBT) Income from Discontinued Operations (2020 - 2021) Analysis & Trends
Purple Biotech (PPBT) has reported Income from Discontinued Operations for 2 consecutive years, with $508000.0 the latest figure, recorded in Q4 2021.
- On a quarterly basis, Income from Discontinued Operations rose 1236.84% year-over-year to $508000.0 in Q4 2021; TTM through Dec 2021 was $796000.0, a N/A change from a year earlier, with the FY2021 full-year figure at $642000.0, up 202.39% from the prior year.
- Income from Discontinued Operations was $508000.0 for Q4 2021 at Purple Biotech, up from $154000.0 in the prior quarter.
- Over five years, Income from Discontinued Operations peaked at $508000.0 in Q4 2021 and troughed at -$2000.0 in Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | Purple Biotech | 286,924.75 | 228,924.75 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 508,000.00 |
| Sep 30, 2021 | 154,000.00 |
| Jun 30, 2021 | -2,000.00 |
| Mar 31, 2021 | 136,000.00 |
| Dec 31, 2020 | 38,000.00 |